Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
18 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001559-C
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Recruitment has not started
18-120 Years
NCI
Melanoma
000958-C
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
18-125 Years
NCI
Melanoma
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Melanoma
000251-C
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Participants currently recruited/enrolled
18-120 Years
NCI
Melanoma
19-C-0010
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Melanoma
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-99 Years
NCI
Melanoma
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-72 Years
NCI
Melanoma
16-C-0066
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Completed Study; data analyses ongoing
18-120 Years
NCI
Melanoma
16-C-0027
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Clinical hold/Recruitment or enrollment suspended
18-70 Years
NCI
Melanoma
14-C-0059
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors
Completed Study; data analyses ongoing
1-35 Years
NCI
Melanoma
14-C-0022
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
Completed Study; data analyses ongoing
18-70 Years
NCI
Melanoma
11-C-0123
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with
No longer recruiting/follow-up only
18-66 Years
NCI
Melanoma
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Melanoma
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Melanoma
03-C-0277
Cell Harvest and Preparation for Surgery Branch Treatment Protocols
Enrolling by Invitation
18-125 Years
NCI
Melanoma
02-C-0211
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Participants currently recruited/enrolled
0-125 Years
NCI
Melanoma
01-C-0129
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
Enrolling by Invitation
0-125 Years
NCI
Melanoma
99-C-0128
Evaluation for NCI Surgery Branch Clinical Research Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Melanoma